ImmuCell Corp. (ICCC) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026. ImmuCell Corporation is an animal health biologics company focused on neonatal dairy and beef calves, primarily through its First Defense product line. The company operates two reportable segments: Scours (First Defense) and Mastitis (CMT and Re-Tain). Sales are seasonal, with Q1 typically driven by the beef calving season.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Product Sales | $10,357,295 | $8,067,174 |
| Gross Profit | $4,657,444 | $3,353,972 |
| Gross Margin | 45.0% | 41.6% |
| Net Operating Income | $1,969,316 | $1,117,624 |
| Net Income | $1,941,607 | $1,446,983 |
| Diluted EPS | $0.21 | $0.16 |
| Cash and Equivalents | $6,812,637 | $4,599,371 |
| Total Debt (Carrying Value) | $8,702,266 | $9,099,107 |
| Operating Cash Flow | $3,573,031 | $1,573,836 |
Material Changes vs. Prior Period
- Revenue Growth: Product sales increased 28.4% year-over-year, driven by higher volumes of Tri-Shield and Dual Force products and price increases effective January 1, 2026. Domestic sales rose 35.7%, while international sales declined 30.2%.
- Expense Shifts: Product development expenses decreased 58.0% due to a strategic decision in December 2025 to cease FDA approval efforts for the Re-Tain product. Approximately $0.3 million in related depreciation and facility costs were reclassified from product development to Cost of Goods Sold (COGS).
- Accounting Estimate Change: The company increased the estimated useful life of certain idle manufacturing equipment by a weighted average of five years. This reduced depreciation expense by $0.1 million, increasing net income by $0.01 per share.
- One-Time Items: Q1 2025 included a $0.4 million insurance recovery for business interruption, which was absent in Q1 2026, contributing to a decrease in "Other income, net."
- Liquidity: Cash and cash equivalents increased by $3.0 million, primarily due to strong operating cash flows and reduced capital expenditures.
Outlook, Risks, and Unusual Items
- Subsequent Event: On May 8, 2026, the company entered a Settlement Deed with Norbrook Laboratories Limited, agreeing to a payment of $2,000,000 to resolve claims related to a 2019 agreement. This is a material non-recurring cash inflow expected in the near term.
- Strategic Pivot: The company is refitting the former Re-Tain facility to increase production capacity for the First Defense line. Approximately $12.3 million of assets remain idle during this transition.
- Debt Profile: The company refinanced certain loans in late 2025 to remove balloon payments due in Q3 2026. Total debt carries a blended fixed interest rate of 4.3%. A $1.0 million line of credit remains available with no outstanding balance.
- Risks: Key risks include seasonality of sales, supply chain disruptions, customer concentration (top three customers represented 60% of sales in Q1 2026), and the success of the facility refit project.
Investor Verification Checklist
- Verify the timing and certainty of the $2.0 million settlement payment from Norbrook Laboratories.
- Monitor the progress of the facility refit and the timeline for bringing the $12.3 million in idle assets back into production.
- Assess the sustainability of the 28.4% revenue growth given the seasonal nature of the beef calving cycle and potential weather impacts.
- Review the customer concentration risk, as the top three customers accounted for 60% of Q1 2026 sales.
- Confirm the impact of the accounting estimate change on future depreciation schedules and margin projections.